Taiwan’s REGiMMUNE and Europe-based Kiji Therapeutics are merging to create a globally minded regulatory T-cell biotech that already has its eyes set on an IPO.

At a town hall featuring FDA leadership at the AdvaMed MedTech Conference in Toronto, Michelle Tarver, M.D., Ph.D., took the time to introduce—or reintroduce—herself to members of the industry, this time as the acting director of the agency’s Center for Devices and Radiological Health.

Terray Therapeutics has raked in $120 million for a series B fundraise as the AI-focused biotech aims to transform small molecule drug development.

Novartis is paying Chengdu Baiyu Pharmaceutical $70 million to add to its crop of cancer candidates. The deal, which features $1.1 billion in milestones, covers the global rights to a small molecule discovered by a Chinese biotech that has built a business around botanical drugs.

Weeks after penning a $110 million upfront deal with Orano Med for the global rights to a neuroendocrine tumor treatment, Sanofi has returned with 300 million euros ($326 million) to set up a more permanent radioligand project.

Ceribell rang in a $180.3 million IPO last week, with its public debut on the Nasdaq coming in well above its first pricing goal of about $101 million and its stock price trading up about 47% following the launch.

Cell therapy biotech Tolerance Bio has unveiled with $17.2 million and a mission of targeting immune diseases by stretching and saving the function of a key organ.

Big Pharma is sticking to the recent molecular glue investment trend, with Pfizer now the latest major drugmaker to get in on the action.

Johnson & Johnson has burnished the evidence for nipocalimab, adding a sliver of data in adolescents with generalized myasthenia gravis (gMG) to the growing case for its near-approval FcRn blocker.

Transgene’s therapeutic vaccine candidate TG4001 has flunked a phase 2 solid tumor trial. But, while the prospect failed to improve progression-free survival (PFS), the French biotech is continuing to analyze aspects of the data including a “positive efficacy trend” in a prespecified subgroup before deciding on its next steps.